Date: 26th October, 2026

Financial Performance Overview

Q2 FY27 Financial Results (Consolidated)

  • Total Income: ₹72.6 crore vs ₹74.8 crore in Q2 FY26 (3% decline)
  • EBITDA: (₹19.2 crore) vs (₹5.6 crore) in Q2 FY26
  • Profit/(Loss) before Tax: (₹37.4 crore) vs (₹24.4 crore) in Q2 FY26
  • Profit/(Loss) after Tax: (₹37.4 crore) vs (₹24.4 crore) in Q2 FY26

H1 FY27 Financial Results (Consolidated)

  • Total Income: ₹156.9 crore vs ₹166.4 crore in H1 FY26 (6% decline)
  • EBITDA: (₹19.1 crore) vs (₹16.1 crore) in H1 FY26
  • Profit/(Loss) before Tax: (₹56.2 crore) vs (₹57.4 crore) in H1 FY26
  • Profit/(Loss) after Tax: (₹56.1 crore) vs (₹57.4 crore) in H1 FY26

Segment-wise Performance Breakdown

Revenue from Operations (₹ crore)

| Category | Q2FY27 | Q2FY26 | % Change | H1FY27 | H1FY26 | % Change |

| Total Revenue | 72.0 | 73.7 | (2%) | 155.6 | 164.8 | (6%) |

| Enterprise Products | 57.0 | 60.6 | (6%) | 108.7 | 97.1 | 12% |

| Contract Manufacturing & New Products | 15.0 | 13.1 | 15% | 46.9 | 67.7 | (31%) |

Geographic Revenue Breakdown (₹ crore)

| Geography | Q2FY27 | Q2FY26 | % Change | H1FY27 | H1FY26 | % Change |

| Exports | 28.9 | 41.1 | (30%) | 62.2 | 87.0 | (28%) |

| Domestic | 43.1 | 32.6 | 32% | 93.4 | 77.8 | 20% |

Management Commentary

Mr. Vishal Sharma, Chairperson, cited multiple factors affecting performance:

  • Adverse weather conditions in certain regions due to El Niño impact
  • Poor rainfall in many parts of India leading to demand weakening
  • Elevated channel inventories across key agrochemical markets
  • Cautious procurement by customers
  • Channel destocking impacting export sales
  • Overall pricing pressure in export markets
  • Weaker demand across select export markets
  • Ongoing geopolitical uncertainties causing volatility in raw material prices
  • Inventory write-down of ₹3 crore to net realizable value

Performance Drivers

Negative Factors:

  • Lower volumes in key enterprise products
  • Reduced realizations across product portfolio
  • Elevated input costs due to pricing pressures
  • Continued volatility in raw material prices
  • ₹3 crore inventory write-down
  • 30% decline in export sales in Q2 FY27

Positive Factors:

  • Contract Manufacturing & New Products segment grew 15% YoY to ₹15 crore in Q2 FY27
  • Domestic sales increased 32% YoY to ₹43.1 crore in Q2 FY27
  • 20% growth in domestic sales in H1 FY27

Strategic Initiatives

The Company is focused on:

  • Expanding its growth platform through enhanced business development efforts
  • New product introductions
  • Ongoing initiatives to improve capacity utilizations
  • Cost optimization measures
  • Strengthening operational performance

Business Overview

Astec LifeSciences Limited is engaged in manufacturing of agrochemical active ingredients (technical), bulk, formulations and intermediate products. The company has a sales mix of both exports and domestic sales, with exports to United States, Europe, West Asia, South-East Asia, Latin America and Africa.